Hidradenitis suppurativa (HS) Learning Zone
Transcript: Investigational treatments for HS
Dr Thrasyvoulos Tzellos
Interview recorded Sep 2024. All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
In this congress, we saw a lot of the pipeline to come in HS. And indeed, hidradenitis suppurativa is a disease which has, like atopic dermatitis now, an exciting pipeline. So we saw an interesting study regarding upadacitinib. Plasma cell activation, plasma cell activity is an important factor in hidradenitis suppurativa. Upadacitinib has been shown to have a positive effect on plasma cell activity, and it has been shown that a higher baseline activity of plasma cells could predict a positive outcome with upadacitinib. So perhaps we are seeing the first steps in individualised patient treatment approach, finding possible biomarkers that could predict positive effect with different treatments. Furthermore, we saw evidence that interleukin-17F is a highly relevant for deep draining tunnels. And practically, deep draining tunnels are an important part of HS and still an unmet need. That's why it seems that treatments like sonelokimab and bimekizumab have an additive positive effect when inhibiting interleukin-17F along with others.
We saw interesting data regarding NLRP3 inhibition, an inhibition that could facilitate inhibiting different important parts of the disease like interleukin-17, interleukin-36, and interleukin-1. So we start seeing inhibition that works in many different points, thus having the potential to have a broader positive effect against the disease. Of course, phenotype and endotype directed treatment is always a concept, and it seems that we have a phenotype with draining tunnels which response differently to new treatments compared to the standard of care which was adalimumab.
This content has been developed independently by Medthority who previously received educational funding from Novartis Pharma AG in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.